MedTrace Logo

Acetylamantadine Excretion by Cancer Patients

NCT02277938 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2021-03-17

No results posted yet for this study

Summary

Several factors discourage the implementation of cancer screening to the population in general, which would result in earlier diagnosis and an expected improved survival. Concurrent in vivo and in vitro research has shown that drug acetylation activity is increased in cancer. Amantadine may be of value in detecting the presence of cancer. Accordingly, this study will examine how Amantadine is eliminated by the body in cancer patients. This is an important step in validating a cancer detection method that can be implemented economically for screening of large numbers of people.

Conditions

Interventions

DRUG

Amantadine

Amantadine is a drug that has been on the market for several years and is currently approved for the treatment of Parkinson's disease and for prevention against influenza A infection. Amantadine may be of value in detecting the presence of cancer.

Sponsors & Collaborators

  • BioMark Technologies Inc.

    collaborator INDUSTRY

  • St. Boniface Hospital

    collaborator OTHER

  • University of Manitoba

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02277938 on ClinicalTrials.gov